Business Wire

Ant Group Recognized as a Top 100 Global Innovator 2025

13.3.2025 04:44:00 CET | Business Wire | Press Release

Share

Ant Group has been recognized for the fourth consecutive year as one of the Top 100 Global Innovators 2025 by Clarivate, a global leader in providing transformative intelligence, identifies and ranks organizations leading the world in technology research and innovation. This recognition reaffirms Ant Group's ongoing commitment to excellence in innovation, particularly in AI and other critical digital technologies.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250312994412/en/

Clarivate recognizes Ant Group as one of the Top 100 Global Innovators 2025. (Graphic: Business Wire)

Gordon Samson, President, Intellectual Property, Clarivate, said, “Being recognized as a Top 100 Global Innovator is a remarkable achievement given the pace of change - since 2000, we’ve seen an 80-fold increase in the volume of inventions. Competition is more global than ever before, and developments in one region can have a significant global impact. Ant Group has demonstrated extraordinary influence in the industry and achieved significant innovative success on a global scale. We congratulate Ant Group for being named a Top 100 Global Innovator for four consecutive years.”

In recent years, Ant Group has significantly increased its investment in technology, particularly in AI, to drive innovation for consumers, small businesses, and partners. Its latest sustainability report shows that R&D spending reached RMB 21.19 billion (USD 2.9 billion) in 2023. As of November 2024, the company had filed 34,576 patent applications globally, with 97% being invention patents.

In 2024, Ant Group launched a series of AI-powered services to enhance user experience, including various AI assistants for everyday services, personal investment, and healthcare. For businesses, Antom Copilot was launched as the world's first AI agent designed to simplify the payment integration and orchestration process for merchants, while Antom Shield uses advanced AI to strengthen fraud detection, optimize conversion rates and drive growth.

To ensure the security and validation of Generative AI, Ant Group has collaborated with leading tech companies and institutions, including OpenAI, Google, and Microsoft, to develop two international industry standards: the “Generative AI Application Security Testing and Validation Standard” and the “Large Language Model Security Testing Method”.

Beyond AI, Ant Group introduced Alipay Tap! in July 2024 to simplify the experience for both businesses and consumers. This feature speeds up in-store mobile payments by allowing users to tap their unlocked phones against a merchant's USB checkout device, significantly enhancing merchant checkout efficiency, especially during peak hours. In addition to payments, Alipay Tap! simplifies access to a wide range of everyday services. For example, users can tap to order food at restaurants, unlock vending machines, rent power banks, and more. As of November 2024, Alipay Tap! has been adopted by businesses in over 100 major cities across China, available in over 1,000 shopping malls and commercial districts.

With its continued focus on AI, digital innovation, and global collaboration, Ant Group remains committed to shaping the future of technology and delivering enhanced digital experiences for users and businesses.

Methodology

The Top 100 Global Innovators uses a complete comparative analysis of global invention data to assess the strength of every patented idea, using measures tied directly to their innovative power. To move from the individual strength of inventions to identifying the organizations that create them more consistently and frequently, Clarivate sets two threshold criteria that potential candidates must meet and then adds a measure of their patented innovation output over the past five years. For full information, please visit the Top 100 Global Innovators 2025 methodology site.

About Clarivate

Clarivate is a leading global provider of transformative intelligence. We offer enriched data, insights & analytics, workflow solutions and expert services in the areas of Academia & Government, Intellectual Property and Life Sciences & Healthcare. For more information, please visit www.clarivate.com

About Ant Group

Ant Group aims to build the infrastructure and platforms to support the digital transformation of the service industry. Through continuous innovation, we strive to provide all consumers and small and micro businesses equal access to digital financial and other daily life services that are convenient, sustainable and inclusive.

For more information, please visit our website at www.antgroup.com or follow us on Twitter @AntGroup.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250312994412/en/

Contacts

Media inquiries:
Clarivate
Sofía Nogués
newsroom@clarivate.com

Ant Group
Yinan Duan
duanyinan.dyn@antgroup.com

(c) 2024 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press Release

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:19:00 CEST | Press Release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press Release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press Release

inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and

Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press Release

Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by up to 97% within two months, TP53 and KRAS mutations near undetectable. Immune activity (first six patients): STC-1010 regimen nearly quadrupled cytotoxi

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye